Standard BioTools Q3 2023 EPS $(0.27) Down From $(0.26) YoY, Sales $25.37M Down From $25.65M YoY
Portfolio Pulse from vinayak@benzinga.com
Standard BioTools (NASDAQ:LAB) reported Q3 2023 losses of $(0.27) per share, a 3.85% decrease YoY. The company also reported sales of $25.37M, a 1.09% decrease YoY.
November 07, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Standard BioTools reported a YoY decrease in both EPS and sales for Q3 2023. EPS decreased by 3.85% and sales decreased by 1.09%.
Standard BioTools reported a decrease in both EPS and sales for Q3 2023 compared to the same period last year. This negative financial performance could potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100